SEC Form 4 · accession 0001179110-15-004403

ACCELERON PHARMA INC · XLRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Ravindra Kumar

Officer — VP & Chief Scientific Officer

Period of report

Mar 4, 2015

Accepted (ET)

Mar 6, 2015 · 4:08 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001280600

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 4, 2015	M	500	$5.88	A	35,200	D
Common Stock	Mar 4, 2015	M	3,500	$5.88	A	38,700	D
Common Stock^F2	Mar 4, 2015	S	2,086	$40.56	D	36,614	D
Common Stock^F3	Mar 4, 2015	S	1,614	$41.22	D	35,000	D
Common Stock^F4	Mar 4, 2015	S	300	$42.06	D	34,700	D
Common Stock^F5	Mar 4, 2015	S	1,034	$40.62	D	33,666	D
Common Stock^F6	Mar 4, 2015	S	366	$41.09	D	33,300	D
Common Stock	Mar 4, 2015	S	100	$42.04	D	33,200	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Stock^F7	$5.88	Mar 4, 2015	M	500	D	—	Dec 17, 2018	Common Stock	500	0	D
Option to Purchase Common Stock^F7	$5.88	Mar 4, 2015	M	3,500	D	—	Dec 2, 2019	Common Stock	3,500	0	D

Explanation of responses

F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.96, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $42.00, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.08, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.90, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $41.28, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
F7The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.